{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:46:41Z","timestamp":1793710001492,"version":"4.6.1"},"reference-count":65,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Rifampin is a crucial antibiotic in the management of prosthetic joint infections (PJI), particularly due to its effectiveness against staphylococcal bacteria and its ability to penetrate and disrupt biofilms. This review evaluates rifampin\u2019s role by examining its mechanism of action, clinical efficacy, and integration into treatment regimens based on recent evidence and guidelines. Rifampin\u2019s synergistic effects with other antibiotics, such as \u03b2-lactams and vancomycin, enhance bacterial eradication, and some evidence shows that it improves patient outcomes. However, evidence supporting its use is limited by the scarcity of robust human clinical trials, and challenges such as potential drug interactions and resistance development necessitate careful management. Ongoing research is needed to refine its use and address existing limitations in clinical practice.<\/jats:p>","DOI":"10.3390\/antibiotics13121223","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T05:26:02Z","timestamp":1734413162000},"page":"1223","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Role of Rifampin in Prosthetic Joint Infections: Efficacy, Challenges, and Clinical Evidence"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0067-2416","authenticated-orcid":false,"given":"Jakrapun","family":"Pupaibool","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1128\/AAC.46.3.900-903.2002","article-title":"Penetration of rifampin through Staphylococcus epidermidis biofilms","volume":"46","author":"Zheng","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e01746-18","DOI":"10.1128\/AAC.01746-18","article-title":"Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections","volume":"63","author":"Zimmerli","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1093\/clinids\/5.Supplement_3.S428","article-title":"Pharmacokinetics and metabolism of rifampin in humans","volume":"5","author":"Acocella","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1378\/chest.115.1.12","article-title":"Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids","volume":"115","author":"Peloquin","year":"1999","journal-title":"Chest"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/bcp.15298","article-title":"Population pharmacokinetics analyses of rifampicin in adult and children populations: A systematic review","volume":"88","author":"Muda","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: An updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_7","first-page":"S313","article-title":"The Concise Guide To Pharmacology 2021\/22: Enzymes","volume":"178","author":"Alexander","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Xu, R.J., Ling, T., Tang, H., Ge, W.H., and Jiang, Q. (2021). Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.706781"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/1471-0528.15027","article-title":"Drug interactions between rifamycin antibiotics and hormonal contraception: A systematic review","volume":"125","author":"Simmons","year":"2018","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/bmj.286.6369.923","article-title":"Rifampicin reduces effectiveness and bioavailability of prednisolone","volume":"286","author":"McAllister","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Butranova, O.I., Ushkalova, E.A., Zyryanov, S.K., and Chenkurov, M.S. (2023). Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030940"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1093\/clinids\/5.Supplement_3.S440","article-title":"Adverse effects of rifampin","volume":"5","author":"Grosset","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18488","DOI":"10.3390\/ijms140918488","article-title":"Novel strategies for the prevention and treatment of biofilm related infections","volume":"14","author":"Chen","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sharma, S., Mohler, J., Mahajan, S.D., Schwartz, S.A., Bruggemann, L., and Aalinkeel, R. (2023). Microbial Biofilm: A Review on Formation, Infection, Antibiotic Resistance, Control Measures, and Innovative Treatment. Microorganisms, 11.","DOI":"10.3390\/microorganisms11061614"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1469-0691.2006.01463.x","article-title":"Treatment of acute post-surgical infection of joint arthroplasty","volume":"12","author":"Soriano","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1469-0691.2007.01691.x","article-title":"Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid","volume":"13","author":"Aboltins","year":"2007","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/39.2.235","article-title":"Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin","volume":"39","author":"Drancourt","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Tonnelier, M., Bouras, A., Joseph, C., Samad, Y.E., Brunschweiler, B., Schmit, J.L., Mabille, C., and Lanoix, J.P. (2021). Impact of rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp.: A retrospective single-center study in France. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-05832-2"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s10096-015-2404-z","article-title":"Influence of daily dosage and frequency of administration of rifampicin-levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infections","volume":"34","author":"Nguyen","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dky152","article-title":"Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: A systematic review and meta-analysis","volume":"73","author":"Stott","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/cid\/cit186","article-title":"Dosing rifampin","volume":"57","author":"Fierer","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/cid\/cit189","article-title":"Reply to Eisen and Denholm, Dauchy et al., Fierer, and Nguyen and Jones","volume":"57","author":"Osmon","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Huang, J., Zhang, F., Zhang, J., Dai, J., Rong, D., Zhao, M., Wang, J., Ding, Y., Chen, M., and Xue, L. (2021). Molecular Characterization of Rifampicin-Resistant Staphylococcus aureus Isolates from Retail Foods in China. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121487"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jgar.2021.12.005","article-title":"Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea","volume":"28","author":"Lee","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Maudsdotter, L., Ushijima, Y., and Morikawa, K. (2019). Fitness of Spontaneous Rifampicin-Resistant Staphylococcus aureus Isolates in a Biofilm Environment. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00988"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1128\/AAC.00398-11","article-title":"Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3","volume":"55","author":"Matsuo","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1128\/JCM.02144-10","article-title":"Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus","volume":"49","author":"Watanabe","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1128\/AAC.00437-10","article-title":"An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus","volume":"54","author":"Cui","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1128\/AAC.00720-13","article-title":"Mutation of RNA polymerase \u03b2-subunit gene promotes heterogeneous-to-homogeneous conversion of \u03b2-lactam resistance in methicillin-resistant Staphylococcus aureus","volume":"57","author":"Aiba","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/cid\/ciab426","article-title":"If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study","volume":"73","author":"Beldman","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s13018-020-01877-2","article-title":"Rifampin combination therapy in staphylococcal prosthetic joint infections: A randomized controlled trial","volume":"15","author":"Karlsen","year":"2020","journal-title":"J. Orthop. Surg. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/cid\/ciw665","article-title":"A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug-Drug Interaction","volume":"63","author":"Pushkin","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7150\/jbji.40333","article-title":"Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): A retrospective multicenter study in France","volume":"5","author":"Becker","year":"2020","journal-title":"J. Bone Jt. Infect."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10096-010-0952-9","article-title":"Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention","volume":"29","author":"Berbari","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/17453674.2015.1026756","article-title":"75% success rate after open debridement, exchange of tibial insert, and antibiotics in knee prosthetic joint infections","volume":"86","author":"Holmberg","year":"2015","journal-title":"Acta Orthop."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.arth.2022.03.072","article-title":"The Use of Rifampin in Total Joint Arthroplasty: A Systematic Review and Meta-Analysis of Comparative Studies","volume":"37","author":"Kruse","year":"2022","journal-title":"J. Arthroplast."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bjerg, C.S.B., Poehlein, A., B\u00f6meke, M., Himmelbach, A., Schramm, A., and Br\u00fcggemann, H. (2024). Increased biofilm formation in dual-strain compared to single-strain communities of Cutibacterium acnes. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-65348-y"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Varin-Simon, J., Colin, M., Velard, F., Tang-Fichaux, M., Ohl, X., Mongaret, C., Gangloff, S.C., and Reffuveille, F. (2024). Cutibacterium acnes biofilm formation is influenced by bone microenvironment, implant surfaces and bacterial internalization. BMC Microbiol., 24.","DOI":"10.1186\/s12866-024-03422-1"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Yadav, P., Verma, S., Bauer, R., Kumari, M., Dua, M., Johri, A.K., Yadav, V., and Spellerberg, B. (2020). Deciphering Streptococcal Biofilms. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111835"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1172\/JCI200320430","article-title":"Quorum sensing and biofilm formation in Streptococcal infections","volume":"112","author":"Cvitkovitch","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00264-020-04722-7","article-title":"Factors affecting outcome in the treatment of streptococcal periprosthetic joint infections: Results from a single-centre retrospective cohort study","volume":"45","author":"Andronic","year":"2021","journal-title":"Int. Orthop."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijid.2019.06.012","article-title":"The prognosis of streptococcal prosthetic bone and joint infections depends on surgical management-A multicenter retrospective study","volume":"85","author":"Mahieu","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jinf.2018.07.014","article-title":"Clinical outcome and risk factors for failure in late acute prosthetic joint infections treated with debridement and implant retention","volume":"78","author":"Sebillotte","year":"2019","journal-title":"J. Infect."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fiaux, E., Titecat, M., Robineau, O., Lora-Tamayo, J., El Samad, Y., Etienne, M., Frebourg, N., Blondiaux, N., Brunschweiler, B., and Dujardin, F. (2016). Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1889-0"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/17453674.2015.1094613","article-title":"Treatment of prosthetic joint infections due to Propionibacterium. Similar results in 60 patients treated with and without rifampicin","volume":"87","author":"Jacobs","year":"2016","journal-title":"Acta Orthop."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1064","DOI":"10.1093\/cid\/ciaa1839","article-title":"The Impact of Surgical Strategy and Rifampin on Treatment Outcome in Cutibacterium Periprosthetic Joint Infections","volume":"72","author":"Kusejko","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1128\/AAC.38.12.2798","article-title":"Possible implications of doxycycline-rifampin interaction for treatment of brucellosis","volume":"38","author":"Colmenero","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Okazaki, F., Tsuji, Y., Seto, Y., Ogami, C., Yamamoto, Y., and To, H. (2019). Effects of a rifampicin pre-treatment on linezolid pharmacokinetics. PLoS ONE, 14.","DOI":"10.1101\/572610"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1128\/AAC.45.11.3238-3241.2001","article-title":"Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients","volume":"45","author":"Ribera","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"106885","DOI":"10.1016\/j.ijantimicag.2023.106885","article-title":"Pharmacokinetic interaction between rifampicin and clindamycin in staphylococcal osteoarticular infections","volume":"62","author":"Goulenok","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s15010-015-0773-y","article-title":"Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections","volume":"43","author":"Curis","year":"2015","journal-title":"Infection"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jinf.2015.03.013","article-title":"Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination","volume":"71","author":"Bernard","year":"2015","journal-title":"J. Infect."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1093\/jac\/dks306","article-title":"Sulfamethoxazole enhances the antimycobacterial activity of rifampicin","volume":"67","author":"Macingwana","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1128\/AAC.00832-12","article-title":"The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis","volume":"56","author":"Jacobs","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Karabay, O., Sencan, I., Kayas, D., and Sahin, I. (2004). Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: A randomized clinical trial [ISRCTN11871179]. BMC Infect. Dis., 4.","DOI":"10.1186\/1471-2334-4-18"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.2147\/DDDT.S341242","article-title":"Clinical Effect of Doxycycline Combined with Compound Sulfamethoxazole and Rifampicin in the Treatment of Brucellosis Spondylitis","volume":"15","author":"Yang","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2106\/JBJS.16.01002","article-title":"Oral-Only Linezolid-Rifampin Is Highly Effective Compared with Other Antibiotics for Periprosthetic Joint Infection: Study of a Mouse Model","volume":"99","author":"Thompson","year":"2017","journal-title":"J. Bone Jt. Surg. Am. Vol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/jac\/dkv481","article-title":"Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention","volume":"71","author":"Tornero","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijantimicag.2010.07.008","article-title":"Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis","volume":"36","author":"Lefebvre","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijantimicag.2013.05.019","article-title":"Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model","volume":"42","author":"Baldoni","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1128\/AAC.00361-08","article-title":"Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus","volume":"52","author":"Belley","year":"2008","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/12\/1223\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:53:44Z","timestamp":1760115224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/12\/1223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":65,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["antibiotics13121223"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13121223","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}